FOLFIRI Protocol

DRUG14 trials

Sponsors

Federation Francophone de Cancerologie Digestive, Peking University, AIO-Studien-gGmbH, Massachusetts General Hospital, Rabin Medical Center

Conditions

Advanced CancerBrain Metastases, AdultCastration-resistant Prostate CancerCervical CancerColorectal CancerDiffuse Astrocytoma, IDH-MutantEsophageal CancerEsophageal Squamous Cell Carcinoma

Phase 1

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Scandion Oncology A/SMetastatic Colorectal Cancer

Start: 2020-05-14End: 2022-06-30Target: 35Updated: 2022-03-02

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

TerminatedNCT05084859

Biosplice Therapeutics, Inc.Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer

Start: 2021-11-03End: 2022-10-20Updated: 2024-08-09

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

RecruitingNCT06047379

Neonc Technologies, Inc.Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer +18

Start: 2023-11-01End: 2027-08-31Target: 134Updated: 2026-03-02

Phase 2

Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

CompletedNCT02181556

Federation Francophone de Cancerologie DigestiveMetastatic Colorectal Cancer

Start: 2014-10-31End: 2017-07-31Updated: 2021-06-07

Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

Peking UniversityNeuroendocrine Carcinoma

Start: 2017-05-02End: 2020-05-02Target: 45Updated: 2017-06-01

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

CompletedNCT03186326

Federation Francophone de Cancerologie DigestiveMetastatic Colorectal Cancer, MSI

Start: 2018-04-24End: 2025-03-01Updated: 2025-06-29

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

TerminatedNCT03331640

AIO-Studien-gGmbHMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2018-01-02End: 2021-09-13Updated: 2022-01-11

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruitingNCT03959293

Federation Francophone de Cancerologie DigestiveGastric Adenocarcinoma, Gastric Cancer

Start: 2019-07-17End: 2024-11-27Updated: 2024-07-08

Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

Rabin Medical CenterLiver Metastasis Colon Cancer

Start: 2020-01-01End: 2022-01-31Target: 49Updated: 2020-10-20

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Active, not recruitingNCT04587128

University of Wisconsin, MadisonMetastatic Colorectal Cancer

Start: 2020-10-19End: 2029-10-01Updated: 2026-02-05

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

TerminatedNCT05039944

Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer

Start: 2021-11-30End: 2022-06-06Updated: 2024-07-18

RP-6306 in Patients With Advanced Cancer

CompletedNCT05605509

Canadian Cancer Trials GroupAdvanced Cancer

Start: 2023-05-24End: 2026-02-05Updated: 2026-02-06

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

Not yet recruitingNCT07359456

UNICANCERMetastatic Colorectal Cancer

Start: 2026-03-01End: 2032-03-01Target: 130Updated: 2026-01-22

Phase 3

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

RecruitingNCT03803553

Massachusetts General HospitalMetastatic Colon Cancer, Stage III Colon Cancer

Start: 2020-04-16End: 2027-12-31Target: 400Updated: 2025-12-23

Related Papers

Abstract 1167: The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of pediatric medulloblastoma patient-derived orthotopic xenograft mouse models.

Cancer Research2026-04-03

Phase II trial of early-line anti-EGFR therapy to facilitate retreatment for select patients with metastatic colorectal cancer.

Journal of Clinical Oncology2026-01-10

Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

JAMA Oncology2025-06-185 citations

Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

Communications Medicine2025-04-243 citations

PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.

2025-04-241 citations

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

2024-06-019 citations

Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial).

Journal of Clinical Oncology2024-01-209 citations

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability

JAMA Oncology2023-08-0336 citations

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

BMC Cancer2023-03-2026 citations

The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

Journal of Clinical Oncology2022-06-015 citations

Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.

Journal of Clinical Oncology2022-01-19

Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.

Journal of Clinical Oncology2022-01-19

Abstract P077: SCO-101 mediates re-sensitization of irinotecan (SN38) resistant colorectal cancer cells

Molecular Cancer Therapeutics2021-12-011 citations

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

BMJ Open2021-09-0142 citations

Abstract PS17-43: Sco-101 is a novel oral drug that reverses antiestrogen resistance in breast cancer cells

Cancer Research2021-02-15

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

2020-12-2521 citations

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

2020-08-3123 citations

Abstract A024: Preventing PROGRESSION

Cancer Epidemiology Biomarkers & Prevention2020-06-01